University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...
ETHealthworld.com brings latest bdr pharma news, views and updates from all top sources for the Indian Health industry.
"Cicada" is trending, but not because it's the season for the noisy insects to appear. The Centers for Disease Control and Prevention and the World Health Organization are both monitoring a COVID-19 ...
Asianet Newsable on MSN
Silent killer? How air pollution is linked to ILD and lung damage
Although there are more than 100 types of ILD with different etiologies, the usual trigger is most commonly smoking for prolonged years. Pollution in the environment, whether a trigger or just an ...
Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...
Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...
“She never wanted anyone to have to naively be in pain without answers," Dern tells PEOPLE of her mother, who died in November 2025 Bailey Richards is a Writer-Reporter at PEOPLE. She has been working ...
Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to ...
The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...
What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, ...
More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results